Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920300's EV-to-FCF is ranked worse than 90.57% of 1707
companies
in the Industrial Products industry
Industry Median: 24.79
vs BJSE:920300: 180.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Chenguang Medical Technologies Co (BJSE:920300) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Chenguang Medical Technologies Co's PE Ratio (TTM) for today is calculated as:
Shanghai Chenguang Medical Technologies Co's share price for today is ¥9.47.
Shanghai Chenguang Medical Technologies Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai Chenguang Medical Technologies Co EV-to-FCF Related Terms
Shanghai Chenguang Medical Technologies Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Chenguang Medical Technologies Co EV-to-FCF Chart
Shanghai Chenguang Medical Technologies Co Annual Data
For the Electrical Equipment & Parts subindustry, Shanghai Chenguang Medical Technologies Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Chenguang Medical Technologies Co EV-to-FCF vs Industrial Products Industry
Shanghai Chenguang Medical Technologies Co's current Enterprise Value is ¥927.74 Mil.
Shanghai Chenguang Medical Technologies Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Chenguang Medical Technologies Co (BJSE:920300) has a EV-to-FCF of 176.95 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Chenguang Medical Technologies Co and its competitors. According to the industry distribution chart, Shanghai Chenguang Medical Technologies Co ranks #1546 out of 1707 companies in the Industrial Products industry, placing it in the top 90.6%.
Is Shanghai Chenguang Medical Technologies Co's EV-to-FCF too high?
Shanghai Chenguang Medical Technologies Co's current EV-to-FCF is 176.95. The Industrial Products industry median EV-to-FCF is 24.79. Shanghai Chenguang Medical Technologies Co's value of 176.95 is 613.8% above this industry median. Based on the distribution chart, Shanghai Chenguang Medical Technologies Co ranks #1546 out of 1707 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Shanghai Chenguang Medical Technologies Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Chenguang Medical Technologies Co's EV-to-FCF compare to VRT and BE?
According to the Industrial Products industry distribution chart, Shanghai Chenguang Medical Technologies Co ranks #1546 out of 1707 companies for EV-to-FCF. This places Shanghai Chenguang Medical Technologies Co in the lower half of its industry. The industry median EV-to-FCF is 24.79. Shanghai Chenguang Medical Technologies Co's value of 176.95 is 613.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Industrial Products company?
The median EV-to-FCF among Industrial Products companies is 24.79, based on 1,707 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Chenguang Medical Technologies Co's current EV-to-FCF of 176.95 is 613.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Chenguang Medical Technologies Co and its competitors. For the Industrial Products industry, the median EV-to-FCF is 24.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Chenguang Medical Technologies Co's current EV-to-FCF is 176.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Chenguang Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Chenguang Medical Technologies Co (BJSE:920300) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥6.57, compared to a current price of ¥9.47 — trading 44.1% above its estimated fair value. The current EV-to-FCF is 176.95 and 613.8% above the Industrial Products industry median of 24.79. Shanghai Chenguang Medical Technologies Co's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai Chenguang Medical Technologies Co (BJSE:920300), the current EV-to-FCF is 176.95 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Chenguang Medical Technologies Co (BJSE:920300) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Chenguang Medical Technologies Co stock appears to be overvalued.
The current stock price of ¥9.47 is trading 44.1% above its estimated GF Value™ of ¥6.57.
GuruFocus considers Shanghai Chenguang Medical Technologies Co to be Significantly Overvalued.
Key valuation signals for BJSE:920300:
EV-to-FCF: 176.95
GF Value™: ¥6.57 vs. price of ¥9.47 (44.1% above fair value)
Industry Position: 613.8% above the Industrial Products median (#1546 of 1707)
No single metric tells the full story. See the BJSE:920300 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Chenguang Medical Technologies Co Ltd engages in research and development, production, and sales of the core hardware of medical imaging superconducting MRI equipment and special magnets in the field of scientific research. The company's product system covers hardware of superconducting MRI devices, including: RF detectors, superconducting magnets, gradient coils, RF amplifiers, gradient amplifiers.
53GF Score
Get the complete analysis for BJSE:920300
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920300 has been successfully added to your 
